A 2-Stage Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Tablets in Healthy Subjects in a Double-blind, Placebo-controlled, Multiple-ascending-dose Stage and an Open-label, Single-dose, Crossover Food-effect Stage
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2016
At a glance
- Drugs IW 1701 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ironwood Pharmaceuticals
- 20 Dec 2016 Status changed from active, no longer recruiting to completed.
- 25 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Nov 2016.
- 25 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2016.